Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English | Polski

Prolib Integro - strona głównaBiblioteka WSB we Wrocławiu

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""Fischer, Rieke N."" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-19 z 19
    Podgląd okładki
    Tytuł :
    Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
    Autorzy :
    Fassunke, Jana
    Müller, FabienneAff2, Aff3
    Keul, Marina
    Michels, Sebastian
    Dammert, Marcel A.Aff2, Aff3
    Schmitt, AnnaAff6, Aff7, Aff8
    Plenker, DennisAff2, Aff3
    Lategahn, Jonas
    Heydt, Carina
    Brägelmann, JohannesAff2, Aff3
    Tumbrink, Hannah L.Aff2, Aff3
    Alber, Yannic
    Klein, SebastianAff1, Aff2, Aff3, Aff9
    Heimsoeth, AlenaAff2, Aff3
    Dahmen, Ilona
    Fischer, Rieke N.
    Scheffler, Matthias
    Ihle, Michaela A.
    Priesner, Vanessa
    Scheel, Andreas H.
    Wagener, Svenja
    Kron, Anna
    Frank, Konrad
    Garbert, KatiaAff2, Aff3
    Persigehl, Thorsten
    Püsken, Michael
    Haneder, Stefan
    Schaaf, Bernhard
    Rodermann, Ernst
    Engel-Riedel, Walburga
    Felip, Enriqueta
    Smit, Egbert F.
    Merkelbach-Bruse, Sabine
    Reinhardt, H. ChristianAff6, Aff7, Aff8
    Kast, Stefan M.
    Wolf, Jürgen
    Rauh, Daniel
    Büttner, ReinhardAff1, Aff3, Aff5
    Sos, Martin L.Aff2, Aff3, Aff6
    Pokaż więcej
    Źródło :
    Nature Communications. 9(1)
    Czasopismo naukowe
    Szczegóły
    Podgląd okładki
    Tytuł :
    Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma
    Autorzy :
    Riedel, Richard
    Michels, Sebastian
    Heydt, Carina
    Siemanowski, Janna
    Kobe, Carsten
    Bunck, Anne
    Schäfer, Stephan
    Fischer, Rieke N.
    Scheffler, Matthias
    Abdulla, Diana S.Y.
    Nogová, Lucia
    Koleczko, Sophia
    Merkelbach-Bruse, Sabine
    Büttner, Reinhard
    Wolf, Jürgen
    Pokaż więcej
    Temat :
    Cancer Research
    Pulmonary and Respiratory Medicine
    Oncology
    Adenocarcinoma
    medicine.disease
    medicine
    Lung cancer
    Biomarker (medicine)
    Cancer research
    Cancer
    KRAS
    medicine.disease_cause
    business.industry
    business
    Tyrosine-kinase inhibitor
    medicine.drug_class
    Crizotinib
    medicine.drug
    Lung
    medicine.anatomical_structure
    respiratory tract diseases
    Dostępność :
    https://explore.openaire.eu/search/publication?articleId=doi_________::07f26c68e988a25a1655bcab07ab8f4b
    Szczegóły
    Podgląd okładki
    Tytuł :
    Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial
    Autorzy :
    Michels, Sebastian
    Massuti, Bartomeu
    Schildhaus, Hans-Ulrich
    Franklin, Jeremy
    Sebastian, Martin
    Felip, Enriqueta
    Grohe, Christian
    Rodriguez-Abreu, Delvys
    Abdulla, Diana S. Y.
    Bischoff, Helge
    Brandts, Christian
    Carcereny, Enric
    Corral, Jesus
    Dingemans, Anne-Marie C.
    Pereira, Eva
    Fassunke, Jana
    Fischer, Rieke N.
    Gardizi, Masyar
    Heukamp, Lukas
    Insa, Amelia
    Kron, Anna
    Menon, Roopika
    Persigehl, Thorsten
    Reck, Martin
    Riedel, Richard
    Rothschild, Sacha I.
    Scheel, Andreas H.
    Scheffler, Matthias
    Schmalz, Petra
    Smit, Egbert F.
    Limburg, Meike
    Provencio, Mariano
    Karachaliou, Niki
    Merkelbach-Bruse, Sabine
    Hellmich, Martin
    Nogova, Lucia
    Buettner, Reinhard
    Rosell, Rafael
    Wolf, Juergen
    Pokaż więcej
    Temat :
    Pulmonary and Respiratory Medicine
    Oncology
    Adenocarcinoma
    medicine.disease
    medicine
    Adverse effect
    medicine.medical_specialty
    Internal medicine
    Response Evaluation Criteria in Solid Tumors
    Clinical endpoint
    Clinical trial
    ROS1
    business.industry
    business
    Crizotinib
    medicine.drug
    Lung cancer
    Targeted treatment
    TP53
    ROS1 REARRANGEMENTS
    ANAPLASTIC LYMPHOMA
    ANTITUMOR-ACTIVITY
    KINASE INHIBITION
    TARGETING ROS1
    ALK
    ADENOCARCINOMA
    CHEMOTHERAPY
    MUTATIONS
    FUSIONS
    Źródło :
    Journal of Thoracic Oncology, 14(7), 1266-1276. Elsevier Science
    Dostępność :
    https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09274df74058250ad1cc1423ee3f46f1
    Szczegóły
    Podgląd okładki
    Tytuł :
    PD-L1 expression in non-small cell lung cancer
    Autorzy :
    Scheel, Andreas H.
    Ansen, Sascha
    Schultheis, Anne M.
    Scheffler, Matthias
    Fischer, Rieke N.
    Michels, Sebastian
    Hellmich, Martin
    George, Julie
    Zander, Thomas
    Brockmann, Michael
    Stoelben, Erich
    Groen, Harry
    Timens, Wim
    Perner, Sven
    von Bergwelt-Baildon, Michael
    Buettner, Reinhard
    Wolf, Juergen
    Pokaż więcej
    Temat :
    Checkpoint inhibition
    early stage NSCLC
    genetic alterations
    immunohistochemistry
    non-small cell lung cancer
    PD-L1
    5H1
    DEATH-LIGAND 1
    ANTIBODY MPDL3280A
    BREAST-CANCER
    NIVOLUMAB
    MELANOMA
    IMMUNE
    TUMOR
    B7-H1
    ADENOCARCINOMA
    PEMBROLIZUMAB
    Źródło :
    OncoImmunology. 5(5)
    Dostępność :
    https://explore.openaire.eu/search/publication?articleId=dris___00893::3a7930a9f6e96e796f779f857148e611
    Szczegóły
    Podgląd okładki
    Tytuł :
    Overcoming EGFR -mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.
    Autorzy :
    Fassunke J; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
    Müller F; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
    Keul M; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
    Michels S; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
    Dammert MA; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
    Schmitt A; Center for Molecular Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.; Department I of Internal Medicine, University Hospital of Cologne, Weyertal 115b, 50931, Cologne, Germany.; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Joseph Stelzmann Str. 26, 50931, Cologne, Germany.
    Plenker D; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
    Lategahn J; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
    Heydt C; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
    Brägelmann J; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
    Tumbrink HL; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
    Alber Y; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
    Klein S; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.; Else Kröner Forschungskolleg Clonal Evolution in Cancer, University Hospital Cologne, Weyertal 115b, 50931, Cologne, Germany.
    Heimsoeth A; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
    Dahmen I; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
    Fischer RN; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
    Scheffler M; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
    Ihle MA; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
    Priesner V; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
    Scheel AH; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
    Wagener S; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
    Kron A; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany.
    Frank K; Section Pneumology, Clinic III of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
    Garbert K; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany.
    Persigehl T; Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
    Püsken M; Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
    Haneder S; Institute of Diagnostic and Interventional Radiology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
    Schaaf B; Hospital Dortmund gGmbH, Muensterstrasse 240, 44145, Dortmund, Germany.
    Rodermann E; Onkologie Rhein-Sieg, Schloßstraße 18, 53840, Troisdorf, Germany.
    Engel-Riedel W; Department of Pneumology, Lung Hospital Cologne Merheim, City of Cologne Municipal Hospitals, Cologne, Germany.
    Felip E; Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
    Smit EF; Thoracic Oncology Service, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.
    Merkelbach-Bruse S; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
    Reinhardt HC; Center for Molecular Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany.; Department I of Internal Medicine, University Hospital of Cologne, Weyertal 115b, 50931, Cologne, Germany.; Cologne Excellence Cluster on Cellular Stress Response in Aging-Associated Diseases, University of Cologne, Joseph Stelzmann Str. 26, 50931, Cologne, Germany.
    Kast SM; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany.
    Wolf J; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany. .
    Rauh D; Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Str. 4a, 44227, Dortmund, Germany. .
    Büttner R; Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. .; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany. .; Lung Cancer Group Cologne and Network Genomic Medicine (Lung Cancer), Department I of Internal Medicine, Center for Integrated Oncology Cologne-Bonn, University Hospital Cologne, Kerpener Str. 62, 50931, Cologne, Germany. .
    Sos ML; Molecular Pathology, Institute of Pathology, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. .; Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, Weyertal 115b, 50931, Cologne, Germany. .; Center for Molecular Medicine Cologne, University of Cologne, Robert-Koch-Str. 21, 50931, Cologne, Germany. .
    Pokaż więcej
    Źródło :
    Nature communications [Nat Commun] 2018 Nov 07; Vol. 9 (1), pp. 4655. Date of Electronic Publication: 2018 Nov 07.
    Typ publikacji :
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms :
    Drug Resistance, Neoplasm/*drug effects
    ErbB Receptors/*antagonists & inhibitors
    Piperazines/*pharmacology
    Protein Kinase Inhibitors/*pharmacology
    Acrylamides ; Aniline Compounds ; Animals ; Cell Line, Tumor ; Disease Progression ; ErbB Receptors/chemistry ; ErbB Receptors/metabolism ; Female ; Humans ; Kinetics ; Mice ; Mice, Nude ; Mutation/genetics ; NIH 3T3 Cells ; Piperazines/chemistry ; Protein Binding/drug effects ; Protein Conformation ; Protein Kinase Inhibitors/chemistry
    Czasopismo naukowe
    Szczegóły
      Wyświetlanie 1-19 z 19

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies